Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Product information and disease descriptionPlace of product in therapyDisease description

Diagnosis

17 evidence topics · 10 sources

Diagnostic testing: AASM 2017 guideline recommendations on polysomnography and home sleep apnea testing

“Diagnostic testing for OSA should be performed in conjunction with a comprehensive sleep evaluation and adequate follow-up. Polysomnography is the standard diagnostic test for the diagnosis of OSA in adult patients in whom there is a concern for OSA based on a comprehensive sleep evaluation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend that clinical tools, questionnaires and prediction algorithms not be used to diagnose OSA in adults, in the absence of polysomnography or home sleep apnea testing. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend that polysomnography, or home sleep apnea testing with a technically adequate device, be used for the diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend that if a single home sleep apnea test is negative, inconclusive, or technically inadequate, polysomnography be performed for the diagnosis of OSA. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend that polysomnography, rather than home sleep apnea testing, be used for the diagnosis of OSA in patients with significant cardiorespiratory disease, potential respiratory muscle weakness due to neuromuscular condition, awake hypoventilation or suspicion of sleep related hypoventilation, chronic opioid medication use, history of stroke or severe insomnia. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest that, if clinically appropriate, a split-night diagnostic protocol, rather than a full-night diagnostic protocol for polysomnography be used for the diagnosis of OSA. (WEAK)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest that when the initial polysomnogram is negative and clinical suspicion for OSA remains, a second polysomnogram be considered for the diagnosis of OSA. (WEAK)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Home sleep apnea testing: candidate criteria, device requirements, and respiratory event index

“An increased risk of moderate to severe OSA is indicated by the presence of excessive daytime sleepiness and at least two of the following three criteria: habitual loud snoring, witnessed apnea or gasping or choking, or diagnosed hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A technically adequate HSAT device incorporates a minimum of the following sensors: nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry; or else PAT with oximetry and actigraphy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A technically adequate diagnostic test includes a minimum of 4 hours of technically adequate oximetry and flow data, obtained during a recording attempt that encompasses the habitual sleep period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Measurement error is inevitable in HSAT, compared against PSG, as standard sleep staging channels are not typically monitored in HSAT (e.g., EEG, EOG and EMG monitoring are not typically performed), which results in use of the recording time rather than sleep time to define the denominator of the respiratory event index (REI; the term used to represent the frequency of apneas and hypopneas derived from HSAT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“HSAT devices that use conventional sensors are unable to detect hypopneas only associated with cortical arousals, which are included in the recommended AHI scoring rule in the AASM Scoring Manual.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Scoring rules: AASM 2012 recommended hypopnea rule with 3% desaturation or arousal, and 4% rule for reimbursement

“Score a respiratory event as a hypopnea if all of the following are met:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The peak signal excursions drop by ≥ 30% of pre-event baseline using nasal pressure (diagnostic study), PAP device flow (titration study), or an alternative hypopnea sensor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The duration of the ≥ 30% drop in signal excursions is ≥ 10 seconds.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There is ≥ 3% oxygen desaturation from pre-event baseline or the event is associated with an arousal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Note: If necessary, the number of hypopneas using a definition requiring ≥ 30% drop in flow for ≥ 10 seconds that is associated with ≥ 4% desaturation may additionally be reported to qualify a patient for PAP reimbursement (e.g., Medicaid or Medicare patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For Medicaid and Medicare patients the use of a hypopnea definition based on a 30% drop in flow and 4% or greater desaturation will need to be used to ensure reimbursement until reimbursement policies are changed to reflect the new hypopnea definition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Medicare coverage thresholds: CPAP national coverage determination, AHI or RDI with 4% desaturation hypopnea rule

“Apnea is defined as a cessation of airflow for at least 10 seconds. Hypopnea is defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% reduction in thoracoabdominal movement or airflow as compared to baseline, and with at least a 4% oxygen desaturation.” (opens the source at this quote in a new tab)

“The AHI and/or RDI may be measured by polysomnography (PSG) in a facility-based sleep study laboratory, or by a Type II home sleep test (HST) monitor, a Type III HST monitor, or a Type IV HST monitor measuring at least 3 channels.” (opens the source at this quote in a new tab)

“An initial 12-week period of CPAP is covered in adult patients with OSA if either of the following criterion using the AHI or RDI are met:” (opens the source at this quote in a new tab)

“AHI or RDI greater than or equal to 15 events per hour, or” (opens the source at this quote in a new tab)

“AHI or RDI greater than or equal to 5 events and less than or equal to 14 events per hour with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease, or history of stroke.” (opens the source at this quote in a new tab)

“If the AHI or RDI is calculated based on less than 2 hours of continuous recorded sleep, the total number of recorded events to calculate the AHI or RDI during sleep testing must be at a minimum the number of events that would have been required in a 2-hour period.” (opens the source at this quote in a new tab)